Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGC-11047 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Cellgate
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CGC-11047 is a polyamine analog developed as an anti-proliferative agent for cancer therapy. It acts by inhibiting polyamine biosynthetic enzymes and inducing catabolic enzymes such as spermidine/spermine N(1)-acetyltransferase (SSAT) and spermine oxidase (SMO), leading to increased reactive oxygen species and antiproliferative effects in tumor cells. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis required for tumor growth. The combination of CGC-11047 with bevacizumab has been investigated in preclinical models and early-phase clinical trials for advanced solid tumors and lymphomas to assess safety, tolerability, and potential synergistic antitumor activity[3][5][6][8].
- Brand names
- AvastinAlymsysJobevneMvasiVegzelmaZirabev
- Other names
- bevacizumab
02
Targets
Beyond the preview
Go deeper on CGC-11047 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGC-11047 + bevacizumab.